Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus in humans
Researchers have discovered that the Ervebo Ebola vaccine induces T-cell cross-reactivity against the Bundibugyo virus in humans. This finding suggests the existing vaccine may offer broader protection than previously understood.
Why it matters
This scientific breakthrough could be critical in managing future outbreaks of the Bundibugyo virus, which currently lacks a dedicated vaccine.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources The rVSVΔG-ZEBOV-GP (Ervebo; Merck Sharp & Dohme) is a highly efficacious vaccine against Ebola virus. Credit: Deutsches Museum/Alexander Goettert The current Bundibugyo Ebola virus (BDBV) outbreak in the Democratic Republic of the Congo is the second largest Ebola outbreak worldwide, with over 6,000 confirmed cases and a 48% fatality rate. There is currently no approved BDBV vaccine.
The VSV-EBOV (Ervebo) vaccine, which was developed to combat the related Ebola virus (EBOV), has shown partial cross-protection in non-human primates and has induced BDBV-reactive antibodies in humans.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in